keyword
https://read.qxmd.com/read/38636096/expression-of-bile-acid-receptors-and-transporters-along-the-intestine-of-patients-with-type-2-diabetes-and-controls
#1
JOURNAL ARTICLE
Henriette H Nerild, Hannah Gilliam-Vigh, Anne-Marie Ellegaard, Julie L Forman, Tina Vilsbøll, David P Sonne, Andreas Brønden, Filip K Knop
CONTEXT: The enterohepatic circulation of bile acids depends on intestinal absorption by bile acid transporters and activation of bile acid receptors, which stimulates secretion of hormones regulating glucose and lipid metabolism and appetite. Distribution of bile acid transporters and receptors in the human gut and their potential involvement in type 2 diabetes (T2D) pathophysiology remain unknown. OBJECTIVE: We explored the expression of genes involved in bile acid metabolism throughout the intestines of patients with T2D and matched healthy controls...
April 18, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38626632/fibroblast-growth-factor-6
#2
JOURNAL ARTICLE
Jennelle Smith, Loydie A Jerome-Majewska
Fibroblast Growth Factor 6 (FGF6), also referred to as HST2 or HBGF6, is a member of the Fibroblast Growth Factor (FGF), the Heparin Binding Growth Factor (HBGF) and the Heparin Binding Secretory Transforming Gene (HST) families. The genomic and protein structure of FGF6 is highly conserved among varied species, as is its expression in muscle and muscle progenitor cells. Like other members of the FGF family, FGF6 regulates cell proliferation, differentiation, and migration. Specifically, it plays key roles in myogenesis and muscular regeneration, angiogenesis, along with iron transport and lipid metabolism...
April 10, 2024: Differentiation; Research in Biological Diversity
https://read.qxmd.com/read/38527859/exploring-the-modulatory-effects-of-sotagliflozin-on-dyslipidemia-in-mice-the-role-of-glucagon-fibroblast-growth-factor-21-and-glucagon-like-peptide-1
#3
JOURNAL ARTICLE
Nitin J Deshmukh, M S Kalshetti, Mohan Patil, Pankaj Autade, Ganesh V Sangle
Sotagliflozin is the first dual SGLT1/2 inhibitor antidiabetic drug approved by the US Food and Drug Administration for the management of heart failure. SGLT1/2 inhibition is observed to potentiate the secretion of the incretin hormone, glucagon-like peptide-1 (GLP-1). The current preclinical research sought to investigate the effect of sotagliflozin on the secretion of fat-regulating peptides such as GLP-1, glucagon and fibroblast growth factor 21 (FGF21) and their prospective association with sotagliflozin's potential beneficial effects on dyslipidaemia...
May 2024: Clinical and Experimental Pharmacology & Physiology
https://read.qxmd.com/read/38525555/lactiplantibacillus-plantarum-strains-kabp011-kabp012-and-kabp013-modulate-bile-acids-and-cholesterol-metabolism-in-humans
#4
JOURNAL ARTICLE
T Padro, V de Santisteban, P Huedo, M Puntes, M Aguiló, J Espadaler-Mazo, L Badimon
AIMS: Probiotics with high bile salt hydrolase (BSH) activity have shown to promote cardiovascular health. However, their mechanism(s) of action remain poorly understood. Here, we performed a pilot exploratory study to investigate effects of a 4-week intervention with escalating doses of a BSH-active formula containing Lactiplantibacillus plantarum strains KABP011, KABP012 and KABP013 on bile acid (BA), lipid profile and lipoprotein function. METHODS AND RESULTS: Healthy overweight individuals were included in this study...
March 25, 2024: Cardiovascular Research
https://read.qxmd.com/read/38409703/metabolic-derangement-in-non-alcoholic-fatty-liver-disease-opportunities-for-early-diagnostic-and-prognostic-markers
#5
JOURNAL ARTICLE
Verma Abhinav, Rishabh Mittal, Mathiyazhagan Navaneethakannan, Ahirwar Sonu Singh, Mukherjee Sukhes, Kotnis Ashwin
Non-alcoholic fatty liver disease is a globally prevalent disorder that can rapidly progress if not detected early. Currently, no accepted markers exist for early diagnosis and prognosis of NAFLD. This review describes derangement in major metabolic pathways of lipid, carbohydrate, and amino acids in NAFLD. It suggests that measuring levels of thrombospondin, TyG index, asymmetric dimethylarginine, LAL-A, GLP-1, FGF-21, and GSG index are potential markers for early diagnosis of NAFLD. A single marker may not indicate early NAFLD, and further large-scale studies on correlating levels of Thrombospondin-2, triglyceride-glucose index, and FGF-21 with NAFLD are warranted...
February 22, 2024: Current Molecular Medicine
https://read.qxmd.com/read/38333506/the-correlation-between-serum-fibroblast-growth-factor-21-and-the-severity-and-occurrence-of-coronary-artery-disease
#6
JOURNAL ARTICLE
Seema R Sinha, Prem Prakash, J R Keshari, Ravi V Prasad
BACKGROUND: The burden of cardiovascular diseases (CVDs) is increasing worldwide with CVD being one of the leading causes of death, including atherosclerosis, myocardial infarction, cardiomyopathy, and heart failure (HF). Fibroblast growth factor 21 (FGF21) is an endocrine hormone that regulates carbohydrate and lipid metabolism. It exerts direct effects on the cardiovascular system and can serve as an early indicator of CVDs. FGF21's therapeutic properties include reducing obesity, dyslipidaemia, and hyperglycemia, which can help treat metabolic disorders, autophagy, and apoptosis...
January 2024: Curēus
https://read.qxmd.com/read/38238100/circadian-regulation-of-endocrine-fibroblast-growth-factors-on-systemic-energy-metabolism
#7
JOURNAL ARTICLE
Zhenning Yang, Helmut Zarbl, Grace L Guo
The circadian clock is an endogenous biochemical timing system that coordinates the physiology and behavior of organisms to earth's ~24 h circadian day/night cycle. The central circadian clock synchronized by environmental cues hierarchically entrains peripheral clocks throughout the body. The circadian system modulates a wide variety of metabolic signaling pathways to maintain whole-body metabolic homeostasis in mammals under changing environmental conditions. Endocrine fibroblast growth factors (FGFs), namely FGF15/19, FGF21 and FGF23, play an important role in regulating systemic metabolism of bile acids, lipids, glucose, proteins and minerals...
January 18, 2024: Molecular Pharmacology
https://read.qxmd.com/read/38194168/treatment-with-dapagliflozin-increases-fgf-21-gene-expression-and-reduces-triglycerides-content-in-myocardial-tissue-of-genetically-obese-mice
#8
JOURNAL ARTICLE
A Di Vincenzo, M Crescenzi, M Granzotto, M Vecchiato, P Fioretto, R Vettor, M Rossato
BACKGROUND: The association between obesity and some cardiovascular complications such as heart failure (HF) is well established, and drugs affecting adiposity are supposed to be promising treatments for these conditions. The sodium-glucose cotransporter-2 inhibitors (SGLT2i) are antidiabetic drugs showing benefits in patients with HF, despite the underlying mechanisms have not been completely understood yet. SGLT2i are supposed to promote systemic effects, such as triglycerides mobilization, through the enhancement of fibroblast growth factor-21 (FGF-21) activity...
January 9, 2024: Journal of Endocrinological Investigation
https://read.qxmd.com/read/38056616/endocrine-fgfs-and-their-signaling-in-the-brain-relevance-for-energy-homeostasis
#9
REVIEW
Lucas Zangerolamo, Marina Carvalho, Licio A Velloso, Helena C L Barbosa
Since their discovery in 2000, there has been a continuous expansion of studies investigating the physiology, biochemistry, and pharmacology of endocrine fibroblast growth factors (FGFs). FGF19, FGF21, and FGF23 comprise a subfamily with attributes that distinguish them from typical FGFs, as they can act as hormones and are, therefore, referred to as endocrine FGFs. As they participate in a broad cross-organ endocrine signaling axis, endocrine FGFs are crucial lipidic, glycemic, and energetic metabolism regulators during energy availability fluctuations...
December 4, 2023: European Journal of Pharmacology
https://read.qxmd.com/read/38025699/profile-of-the-bile-acid-fxr-fgf15-pathway-in-the-glucolipid-metabolism-disorder-of-diabetic-mice-suffering-from-chronic-stress
#10
JOURNAL ARTICLE
Weijia Cai, Canye Li, Zuanjun Su, Jinming Cao, Zhicong Chen, Yitian Chen, Zhijun Guo, Jian Cai, Feng Xu
BACKGROUND: Imbalances in bile acid (BA) synthesis and metabolism are involved in the onset of diabetes and depression in humans and rodents. However, the role of BAs and the farnesoid X receptor (FXR)/fibroblast growth factor (FGF) 15 signaling pathway in the development of diabetes and depression is still largely unknown. Therefore, we investigated the potential molecular mechanisms of BAs that may be associated with glucolipid metabolism disorders in diabetic mice subjected to chronic stress...
2023: PeerJ
https://read.qxmd.com/read/37920068/establishment-of-a-cell-culture-platform-for-human-liver-organoids-and-its-application-for-lipid-metabolism-research
#11
JOURNAL ARTICLE
Ayane Kuboyama-Sasaki, Yu Takahashi, Chen Xia, Kahori Hiro, Tsuyoshi Kobayashi, Hideki Ohdan, Makoto Shimizu, Yoshio Yamauchi, Hiroshi Kiyono, Ryuichiro Sato
Human liver organoids (HLOs) are reliable tools to represent physiological human liver biology. However, their use is limited especially in basic sciences. One of the reasons for this would be the insufficient systematic methodology to handle HLOs, including culture system, functional assessment, and gene transduction. Here, we generated and characterized mouse L cells stably and simultaneously overexpressing R-spondin1, hepatocyte growth factor, fibroblast growth factor (FGF) 7, and FGF10 via lentiviral transduction...
November 2, 2023: Biotechnology Journal
https://read.qxmd.com/read/37742789/chloroquine-attenuates-diet-induced-obesity-and-glucose-intolerance-through-a-mechanism-that-might-involve-fgf-21-but-not-ucp-1-mediated-thermogenesis-and-inhibition-of-adipocyte-autophagy
#12
JOURNAL ARTICLE
Milene Ortiz-Silva, Bianca F Leonardi, Érique Castro, Álbert S Peixoto, Gustavo R Gilio, Tiago E Oliveira, Caroline A Tomazelli, Maynara L Andrade, Mayara F Moreno, Thiago Belchior, Juliana Magdalon, Thayna S Vieira, Carlos M Donado-Pestana, William T Festuccia
Chloroquine diphosphate (CQ), a weak base used to inhibit autophagic flux and treat malaria and rheumatoid diseases, has been shown, through unknown mechanisms, to improve glucose and lipid homeostasis in patients and rodents. We investigate herein the molecular mechanisms underlying these CQ beneficial metabolic actions in diet-induced obese mice. For this, C57BL6/J mice fed with either a chow or a high-fat diet (HFD) and uncoupling protein 1 (UCP-1) KO and adipocyte Atg7-deficient mice fed with a HFD were treated or not with CQ (60 mg/kg of body weight/day) during 8 weeks and evaluated for body weight, adiposity, glucose homeostasis and brown and white adipose tissues (BAT and WAT) UCP-1 content...
December 1, 2023: Molecular and Cellular Endocrinology
https://read.qxmd.com/read/37739645/effect-of-fish-oil-supplementation-on-the-concentration-of-mirna-122-fgf-21-and-liver-fibrosis-in-patients-with-nafld-study-protocol-for-a-randomized-double-blind-and-placebo-controlled-clinical-trial
#13
JOURNAL ARTICLE
Lygia N Barroso, Jessica Salarini, Nathalie Carvalho Leite, Cristiane A Villela-Nogueira, Alberto Dávalos, Maria das Graças Tavares Carmo, Wilza Arantes Ferreira Peres
BACKGROUND & AIMS: To date, no specific drugs are available for non-alcoholic fatty liver disease (NAFLD), though the effect of fish oil supplementation on improving fibrosis in patients with NAFLD has been evaluated. N-3 polyunsaturated fatty acids (n-3 PUFA) may modulate the concentration of microRNAs (miRNAs) and fibroblast growth factor (FGF)-21, which have been identified as non-invasive markers of liver fibrosis. The present study aims to evaluate whether n-3 PUFA supplementation can modulate miRNA-122 and FGF-21 and improve liver fibrosis and steatosis, measured by transient hepatic elastography (THE), in individuals with NAFLD...
October 2023: Clinical Nutrition ESPEN
https://read.qxmd.com/read/37608351/fgf1-supports-glycolytic-metabolism-through-the-estrogen-receptor-in-endocrine-resistant-and-obesity-associated-breast-cancer
#14
JOURNAL ARTICLE
Marisol Castillo-Castrejon, Barbara Mensah Sankofi, Stevi Johnson Murguia, Abasi-Ama Udeme, Hoaning Howard Cen, Yi Han Xia, Nisha S Thomas, William L Berry, Kenneth L Jones, Vincent R Richard, Rene P Zahedi, Christoph H Borchers, James D Johnson, Elizabeth A Wellberg
BACKGROUND: Obesity increases breast cancer risk and breast cancer-specific mortality, particularly for people with estrogen receptor (ER)-positive tumors. Body mass index (BMI) is used to define obesity, but it may not be the best predictor of breast cancer risk or prognosis on an individual level. Adult weight gain is an independent indicator of breast cancer risk. Our previous work described a murine model of obesity, ER-positive breast cancer, and weight gain and identified fibroblast growth factor receptor (FGFR) as a potential driver of tumor progression...
August 22, 2023: Breast Cancer Research: BCR
https://read.qxmd.com/read/37562970/the-novel-glycopegylated-fgf21-analog-pegozafermin-activates-human-fgf-receptors-and-improves-metabolic-and-liver-outcomes-in-diabetic-monkeys-and-healthy-human-volunteers
#15
JOURNAL ARTICLE
Moti Rosenstock, Leo Tseng, Andrew A Pierce, Elliot Offman, Chao-Yin Chen, R Will Charlton, Maya Margalit, Hank Mansbach
Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). In cell-based assays, pegozafermin had a similar receptor engagement profile as native FGF21, with approximately 8-fold higher potency at FGF receptor 1 (FGFR1). In diabetic monkeys, once-weekly and once-every-two-week regimens of subcutaneous pegozafermin provided rapid and robust benefits on an array of metabolic biomarkers, including triglycerides, cholesterol, fasting glucose, HbA1c, adiponectin, ALT, food intake, and body weight...
August 10, 2023: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/37541847/feto-maternal-cholesterol-transport-regulated-by-%C3%AE-klotho-fgf15-axis-is-essential-for-fetal-growth
#16
JOURNAL ARTICLE
Kanako Kobayashi, Kazuko Iwasa, Rika Azuma-Suzuki, Takeshi Kawauchi, Yo-Ichi Nabeshima
β-Klotho (β-KL) is indispensable to regulate lipid, glucose, and energy metabolism in adult animals. β-KL is highly expressed in the yolk sac, but its role in the developmental stages has not been established. We hypothesized that β-KL is required for metabolic regulation in the embryo and aimed to clarify the role of β-KL during development. Here, we show that β-KL regulates feto-maternal cholesterol transport through the yolk sac by mediating FGF 15 signaling, and also that impairment of the β-KL-FGF15 axis causes fetal growth restriction (FGR)...
October 2023: Life Science Alliance
https://read.qxmd.com/read/37371624/controlled-attenuation-parameter-is-associated-with-a-distinct-systemic-inflammatory-milieu-after-clearance-of-hcv-infection
#17
JOURNAL ARTICLE
Yanqin Du, Tanvi Khera, Zhaoli Liu, Magdalena Tudrujek-Zdunek, Anna Dworzanska, Markus Cornberg, Cheng-Jian Xu, Krzysztof Tomasiewicz, Heiner Wedemeyer
Hepatitis C virus (HCV) infection is closely associated with lipid metabolism defects along with a high prevalence of hepatic steatosis. After HCV clearance, steatosis persists in many patients. However, the reasons behind this phenomenon are not completely clear. To investigate the association between 92 soluble inflammatory mediators (SIMs) and the steatosis grade, we made use of a cohort of 94 patients with chronic HCV infection who cleared HCV after direct-acting antiviral agent (DAA) treatment. Patients were classified into three groups according to their controlled attenuation parameter (CAP)...
May 25, 2023: Biomedicines
https://read.qxmd.com/read/37366486/therapeutic-approaches-for-nonalcoholic-fatty-liver-disease-established-targets-and-drugs
#18
REVIEW
Xiaojing Huang, Huiling Chen, Song Wen, Meiyuan Dong, Ligang Zhou, Xinlu Yuan
Nonalcoholic fatty liver disease (NAFLD), as a multisystemic disease, is the most prevalent chronic liver disease characterized by extremely complex pathogenic mechanisms and multifactorial etiology, which often develops as a consequence of obesity, metabolic syndrome. Pathophysiological mechanisms involved in the development of NAFLD include diet, obesity, insulin resistance (IR), genetic and epigenetic determinants, intestinal dysbiosis, oxidative/nitrosative stress, autophagy dysregulation, hepatic inflammation, gut-liver axis, gut microbes, impaired mitochondrial metabolism and regulation of hepatic lipid metabolism...
2023: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/37283621/serum-fibroblast-growth-factor-21-level-after-an-oral-fat-tolerance-test-is-related-to-postprandial-free-fatty-acid-level
#19
JOURNAL ARTICLE
Xiaolong Li, Kunjie Zheng, Wei Gu, Xiaoyu Hou, Yunpeng Guan, Lifang Liu, Liping Hou, Jianlin Geng, Guangyao Song
PURPOSE: The relationship between blood lipids and fibroblast growth factor (FGF) 21 in the postprandial period remains unclear. To investigate this, we observed the changes in blood lipid levels after an oral fat tolerance test (OFTT) and examined the short-term effects on FGF21. PATIENTS AND METHODS: A total of 158 non-diabetic adult volunteers who underwent OFTT were randomly recruited from the Hebei General Hospital. Participants were stratified into three groups according to fasting and 4-h postprandial triglyceride levels: normal fat tolerance (NFT), impaired fat tolerance (IFT), and hypertriglyceridemia (HTG)...
2023: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/37282749/epigenetic-regulation-of-hepatic-lipid-metabolism-by-dna-methylation
#20
JOURNAL ARTICLE
Shirong Wang, Lin Zha, Xin Cui, Yu-Te Yeh, Ruochuan Liu, Jia Jing, Huidong Shi, Weiping Chen, John Hanover, Jun Yin, Liqing Yu, Bingzhong Xue, Hang Shi
While extensive investigations have been devoted to the study of genetic pathways related to fatty liver diseases, much less is known about epigenetic mechanisms underlying these disorders. DNA methylation is an epigenetic link between environmental factors (e.g., diets) and complex diseases (e.g., non-alcoholic fatty liver disease). Here, it is aimed to study the role of DNA methylation in the regulation of hepatic lipid metabolism. A dynamic change in the DNA methylome in the liver of high-fat diet (HFD)-fed mice is discovered, including a marked increase in DNA methylation at the promoter of Beta-klotho (Klb), a co-receptor for the biological functions of fibroblast growth factor (FGF)15/19 and FGF21...
June 6, 2023: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
keyword
keyword
20561
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.